National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 19195-19196 [06-3517]
Download as PDF
Federal Register / Vol. 71, No. 71 / Thursday, April 13, 2006 / Notices
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, ZEB1 OSR–A M2 S–
NIBIB Conference Grants.
Date: May 1, 2006.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: NIBIB/NIH/OSR, Democracy II, 6707
Democracy Boulevard, 2nd Floor Conference
Room, Bethesda, MD 20892.
Contact Person: David George, Ph.D.,
Director, Office of Scientific Review,
National Institute of Biomedical Imaging and
Bioengineering, 6707 Democracy Blvd., Suite
920, Bethesda, MD 20892, 301–496–8633,
georged1@mail.nih.gov.
Dated: April 4, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–3514 Filed 4–12–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
HSRObinson on PROD1PC61 with NOTICES
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 06–74, Review R21.
VerDate Aug<31>2005
14:20 Apr 12, 2006
Jkt 208001
Date: May 5, 2006.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Telephone Conference Call).
Contact Person: Sooyoun (Sonia) Kim, MS,
Associate SRA, 45 Center Dr., 4An 32B,
Division of Extramural Research, National
Inst. of Dental & Craniofacial Research,
National Institutes of Health, Bethesda, MD
20892, (301) 594–4827,
kims@email.nidr.nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 06–81, Review R21.
Date: May 18, 2006.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Bethesda,
MD 20892 (Telephone Conference Call).
Contact Person: Sooyoun (Sonia) Kim, MS,
Associate SRA, 45 Center Dr., 4An 32B,
Division of Extramural Research, National
Inst. of Dental & Craniofacial Research,
National Institutes of Health, Bethesda, MD
20892, (301) 594–4827,
kims@email.nidr.nih.gov.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel, 06–75, Review of U01s and
R21.
Date: July 19, 2006.
Time: 1 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Yujing Liu, MD, PhD.,
Scientific Review Administrator, National
Institute of Dental & Craniofacial Res., 45
Center Drive, Natcher Building, Rm 4AN38E,
Bethesda, MD 20892, (301) 594–3169,
yujing_liu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: April 4, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–3515 Filed 4–12–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
19195
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel, Conference Grants.
Date: May 1, 2006.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN12, Bethesda, MD 20892. (Virtual
Meeting).
Contact Person: Arthur L. Zachary, PhD,
Office of Scientific Review, National Institute
of General Medical Sciences, National
Institutes of Health, Natcher Building, Room
3AN–12, Bethesda, MD 20892. (301) 594–
2886. zacharya@nigms.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: April 4, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–3516 Filed 4–12–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
E:\FR\FM\13APN1.SGM
13APN1
19196
Federal Register / Vol. 71, No. 71 / Thursday, April 13, 2006 / Notices
HSRObinson on PROD1PC61 with NOTICES
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; The Development of
Monoclonal Antibodies for Type A
Botulinum Neurotoxin.
Date: April 24, 2006.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817 (Telephone Conference
Call).
Contact Person: Eleazar Cohen, PhD,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, Room 3129,
6700 B Rockledge Drive, Bethesda, MD
20892. (301) 435–3564. ec17w@nih.gov.
This notice is being published less than15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Teleconference Review of a
Stem Cell Therapy Program Project
Application.
Date: May 1, 2006.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Room 3118, Bethesda, MD 20817 (Telephone
Conference Call).
Contact Person: Quirijn Vos, PhD,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892. (301) 451–2666. qvos@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Planning (R34) Grants.
Date: May 3, 2006.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817, (Telephone Conference
Call).
Contact Person: Hagit S. David, PhD,
Scientific Review Administrator, Scientific
Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892. (301) 402–4596.
hdavid@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Aug<31>2005
14:20 Apr 12, 2006
Jkt 208001
Dated: April 5, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–3517 Filed 4–12–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Changes to the National Registry of
Evidence-Based Programs and
Practices (NREPP); Correction
Authority: Sec. 501, Pub. L. 106–310.
SUMMARY: The Substance Abuse and
Mental Health Services Administration
(SAMHSA) published a notice regarding
changes to the National Registry of
Evidence-based Programs and Practices
(NREPP) in the March 14, 2006 Federal
Register. This document contained
several comments from the American
Psychological Association’s Division 50
Committee on Evidence-based Practice
that were incorrectly attributed to the
full American Psychological
Association.
FOR FURTHER INFORMATION CONTACT:
Dr.
Kevin Hennessy, (240) 276–2234.
Correction
In the Federal Register of March 14,
2006, FR volume 71, no. 49, the
following comments were attributed to
the American Psychological
Association’s Committee on Evidencebased Practice, and should have been
attributed to the American
Psychological Association’s Division 50
Committee on Evidence-based Practice.
These comments should be corrected as
follows:
Page 13133, Column 3—The
American Psychological Association
(APA) Division 50 Committee on
Evidence-based Practice recommended
greater emphasis on the utility
descriptors (i.e., those items describing
material and resources to support
implementation), stating, ‘‘these are key
outcomes for implementation and they
are not adequately addressed in the
description of NREPP provided to date.
This underscores earlier concerns noted
about the transition from efficacy to
effectiveness.’’ The APA Division 50
committee noted that generalizability of
programs listed on NREPP will remain
an issue until this ‘‘gap between efficacy
and effectiveness’’ is explicitly
addressed under a revised review
system.
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Page 13140, Column 1—the American
Psychological Association (APA)
Division 50 Committee on Evidencebased Practice recommended more
emphasis on the utility descriptors ‘‘as
these are key outcomes for
implementation and they are not
adequately addressed in the description
of NREPP provided to date. This
underscores earlier concerns noted
about the transition from effectiveness
to efficacy.’’
Page 13140, Columns 1 and 2—The
possibility that NREPP will exclude
programs due to lack of funding was a
concern voiced by several organizations,
including the National Association for
Children of Alcoholics, the APA
Division 50 Committee on Evidencebased Practice the National Association
of State Alcohol and Drug Abuse
Directors, Community Anti-Drug
Coalitions of America, and the
California Association of Alcohol and
Drug Program Executives.
Page 13140, Column 3—A number of
respondents noted the proposed NREPP
approach does not acknowledge
provider effects on treatment outcomes.
The APA Division 50 Committee on
Evidence-based Practice wrote,
‘‘Relationship factors in a therapeutic
process may be more important than
specific interventions and may in fact be
the largest determinant in
psychotherapy outcome (see Lambert &
Barley, 2002). How will NREPP address
this concern and make this apparent to
users?’’
Page 13141, Column 2—The APA
Division 50 Committee on Evidencebased Practice suggested that the
proposed NREPP approach does not
adequately distinguish between
‘‘efficacy’’ and ‘‘effectiveness,’’ and
strongly recommended that SAMHSA
look for ways to bridge the two.
Page 13142, Column 1—A group of
university researchers recommended
that for programs to be included in
NREPP, they should be required to
provide statistically significant results
on drug use and/or mental health
outcomes using two-tailed tests of
significance at p <.05. The APA
Division 50 Committee on Evidencebased Practice recommended further
discussion and consideration by NREPP
of the conceptual distinction between
statistical and clinical significance.
Page 13142, Column 3—The APA
Division 50 Committee on Evidencebased Practice argued that ‘‘including
all of these NREPP products is seen as
a desirable feature that reflects the
continuous nature of evidence. This
may also be critical information for
providing reasonable options for
E:\FR\FM\13APN1.SGM
13APN1
Agencies
[Federal Register Volume 71, Number 71 (Thursday, April 13, 2006)]
[Notices]
[Pages 19195-19196]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-3517]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning
[[Page 19196]]
individuals associated with the grant applications, the disclosure of
which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; The Development of Monoclonal
Antibodies for Type A Botulinum Neurotoxin.
Date: April 24, 2006.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Rockledge 6700, 6700B
Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).
Contact Person: Eleazar Cohen, PhD, Scientific Review
Administrator, Scientific Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, Room 3129, 6700 B Rockledge Drive,
Bethesda, MD 20892. (301) 435-3564. ec17w@nih.gov.
This notice is being published less than15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel, Teleconference Review of a Stem
Cell Therapy Program Project Application.
Date: May 1, 2006.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge 6700, 6700B
Rockledge Drive, Room 3118, Bethesda, MD 20817 (Telephone Conference
Call).
Contact Person: Quirijn Vos, PhD, Scientific Review
Administrator, Scientific Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616,
Bethesda, MD 20892. (301) 451-2666. qvos@niaid.nih.gov.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Planning (R34)
Grants.
Date: May 3, 2006.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge 6700, 6700B
Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).
Contact Person: Hagit S. David, PhD, Scientific Review
Administrator, Scientific Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616,
Bethesda, MD 20892. (301) 402-4596. hdavid@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: April 5, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-3517 Filed 4-12-06; 8:45 am]
BILLING CODE 4140-01-M